Express Pharma
Home  »  COVID-19 Updates  »  Bharat Biotech gets DCGI nod for PHASE II trials of COVAXIN

Bharat Biotech gets DCGI nod for PHASE II trials of COVAXIN

The subject expert committee (SEC) has recommended that the trial will be conducted on 380 participants

3 6,553
Read Article

According to a report by The Indian Express, the Drugs Controller General of India (DCGI) has given clearance to Bharat Biotech for conducting Phase II human clinical trials of its indigenously developed Covaxin.

The report informed that the subject expert committee (SEC) has recommended that the trial will be conducted on 380 participants. A letter from Joint Drugs Controller Dr S Eswara Reddy, dated September 3, has notified the company about this.

Reportedly, the first phase of the Covaxin trial was done with 375 participants from across 12 sites.

Zydus Cadila and Serum Institute of India have also started conducting phase II trials for ZyCoV-D and Covishield (by Oxford-AstraZeneca) in India.

3 Comments
  1. Yash Pal says

    Phase 2 trial should have been started by or about 15 Aug. In this emergency situation also, it is take it easy policy

  2. k.k.chatterjee says

    success of united opposition to stall progress at any cost.

  3. Maninder Singh says

    When all vaccine maker starts phase 1 & phase 2 simultaneously why BB vaccine delayed it when india is suffering most ?

Leave A Reply

Your email address will not be published.

 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
close-image